Under pressure: a review of normal-tension glaucoma by MacDonald, Derek
VOL 74  |  NO 4 2012C A N A D I A N  J O U R N A L  O F  O P T O M E T R Y  |  R E V U E  C A N A D I E N N E  D ’ O P T O M É T R I E 33
CLINICAL REVIEW
BY DEREK MACDONALD, OD, FAAO
Introduction
For a disease recognized as acommon cause of  irreversible 
vision loss, a universally agreed-
upon defi nition of  glaucoma re-
mains elusive. Glaucomatous optic
neuropathy (GON) is characterized
by a progressive loss of  retinal
ganglion cells (RGC), resulting in 
an excavated (cupped) optic nerve
head and loss of  visual fi eld sensi-
tivity.1 Primary open-angle glaucoma
(POAG), the most common form
of  the disease in North America 
with a prevalence of  2.1%, has
been described as “a multifactorial
optic neuropathy characterized by 
acquired loss of  retinal ganglion
cells and optic nerve atrophy”.2 This 
defi nition has evolved over time,
with specifi c mention of  intraocu-
lar pressure (IOP) now conspicu-
ously absent. This is at least in part 
in recognition of  the paradox of
ocular hypertension (OHT) without 
accompanying GON, and of  GON
in the presence of  ‘normal’ IOP; it 
could be stated that increased IOP 
is suffi cient, although not necessary, 
for the development of  glaucoma.
Normal-tension glaucoma (NTG)
has been defi ned as POAG with 
untreated IOP within the statistically 
normal range of  15.5 +/-2.6mmHg;
others specify that high-water 
IOP cannot exceed 21mmHg, at 
which point a diagnosis of  POAG 
is established.3
Interestingly, while IOP no longer
defi nes POAG, it does defi ne NTG, 
and remains the single most impor-
tant, and the only currently modifi -
able, risk factor in the development 
of  glaucoma. Further, patients with 
NTG may demonstrate a more
aggressive disease if  left untreated,
but often respond favourably to
IOP-lowering treatment.4 This has
led investigators to suggest that the 
glaucoma pendulum has swung too 
far away from IOP, and that the 
disease may be best defi ned as the 
only pressure-dependent optic neuropathy.5
Indeed, many recommend that the 
concept of  distinct clinical entities
be abandoned in favour of  viewing 
glaucoma as a continuum from pri-
marily IOP-dependent (POAG) to
IOP-independent (NTG) disease.6
Given that as many as fi ve of  every 
ten patients with glaucoma will pres-
ent with statistically normal IOP, an 
understanding of  the multifactorial 
nature of  what this review will term 
NTG is of  critical importance to 
the eye care practitioner.
Epidemiology and 
Risk Factors
Even more than POAG, NTG
tends to be a disease of  the elderly, 
with a prevalence of  1.6% in the 
population over the age of  75; up 
to 30% of  patients with NTG, 
however, will be under the age
of  50.7 Upon diagnosis, the rate
of  progression and response to 
treatment appear unrelated to age.8
There is evidence that NTG is more 
common, more severe, and more 
resistant to treatment in females.9,10
There also appears to be an ethnic
predilection, as upwards of  90% of  
Japanese and Mongolian patients
with POAG present with IOP
less than 21mmHg; Caucasians,
however, tend to manifest more
serious disease.11-13 A family his-
tory of  glaucoma is reported by 
30 to 40% of  patients with NTG. 
Investigators have observed that 
patients with NTG tend to be of  
lower body weight and body-mass 
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index (BMI).14 It has been hypo-
thesized that patients with NTG
tend to be more health-conscious
(in fact, some would suggest health-
anxious), and exhibit more proactive
health behaviour. Myopic patients
may demonstrate progressive GON
in the presence of  low IOP, and
tend to have diffi cult to interpret,
often tilted, optic nerve heads.15,16
While a discussion of  genetics is
beyond the scope of  this review,
upwards of  twenty genes associated
with POAG have been identifi ed,
and there is evidence that several
may be specifi c for NTG. At least 
two gene loci are associated with
NTG and exfoliative glaucoma;
these loci infl uence transform-
ing growth factor beta (TGF-β),
perhaps suggesting a future neuro-
protective target.17,18
Pathophysiology – 
Under Pressure
Although by defi nition NTG
presents with IOP within the
statistically normal range, admit-
tedly an arbitrary construct with no
pathophysiologic meaning, further 
reducing pressure tends to slow 
disease progression, albeit not uni-
versally.19 Nocturnal IOP elevation, 
particularly in concert with noctur-
nal systemic hypotension, is very 
signifi cant; sleep lab and telemetric 
studies demonstrate that as many 
as two out of  every three patients
exhibit maximal IOP outside regular 
offi ce hours.20-22 In recognition
of  the impact of  corneal biome-
chanical properties on applanation
tonometry (AT), and potentially on
ocular integrity itself, these proper-
ties have recently received greater
attention. Patients with NTG tend 
to have central corneal thicknesses 
(CCT) approximately 30 microns
below the population mean of
550 microns, leading some to
hypothesize that a subset of  patients
with POAG are misdiagnosed with 
NTG.23,24 It has been proposed
that the increased prevalence of
NTG among some ethnic groups
(individuals of  Japanese and African 
descent) may be partly attribut-
able to thin CCT.25,26 Interestingly, 
reduced CCT was more common 
in patients with NTG and vascular
dysregulation than in those without,
suggesting more than simply an
underestimation of  IOP.27 While
the Ocular Hypertension Treat-
ment Study (OHTS) did lead to 
fewer patients with OHT and more
patients with ‘normal’ pressures be-
ing treated, the association between
CCT and glaucoma, specifi cally 
whether CCT may be considered 
a proxy for ONH biomechanical
integrity, remains unclear.28 Recently,
the role of  corneal hysteresis (CH), 
refl ecting the cornea’s viscoelastic 
ability to dampen fl uctuations in 
IOP and reduce optic nerve head
(ONH) strain, has received attention
as another potentially important 
biomechanical parameter.29,30 While
infl uenced by CCT, lower CH is
consistently and independently 
associated with an increased risk 
of  GON.31 There is evidence that a
related parameter, corneal resistance
factor (CRF, a measure of  ocular 
rigidity), is similarly reduced in cases
of  concurrently low but fl uctuating 
IOP – that is, NTG.32 Whereas 
attempts to ‘correct’ IOP for CCT
alone have proven ineffective,
‘corneal compensated IOP (IOPcc)’, 
encompassing a more global corneal 
biomechanical analysis, may hold
promise: IOPcc was essentially equal 
to AT in POAG, but signifi cantly 
higher in NTG.33 Whether reduced 
CH and CRF are risk factors for, or 
a result of  glaucoma, and whether 
they will prove to be better proxies 
for ONH biomechanical integrity 
than CCT alone is yet to be deter-
mined; further study is necessary.34
Reduced ocular perfusion is
found in the majority of  patients
with glaucoma, more so in the 
presence of  NTG than POAG.35
Cardiovascular disease, including 
increased blood viscosity, diabetes,
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and both systemic hypertension and
hypotension, has been identifi ed as
a risk factor for the development of
glaucoma, and may be predictive of
a poor response to treatment.36,37 In 
fact, patients tend to show increased
risk of  glaucoma at both extremes
of  blood pressure (BP), albeit more
so with hypotension, which results
in generalized poor perfusion.
Hypertension leads to atherosclero-
sis, damaging endothelial cells and
impairing autoregulation, rendering 
the ONH more susceptible to 
decreased vascular perfusion,
increased IOP, and metabolic 
demands.38 In the Collaborative
Normal-Tension Glaucoma Study 
(CNTGS), patients without cardio-
vascular disease tended to progress
rapidly when untreated, but benefi t-
ted from IOP reduction; vasospastic
disease was more predictive of
progression than occlusive disease.
Magnetic resonance imaging (MRI) 
of  the brain has demonstrated vas-
cular insuffi ciency in patients with
NTG, while cardiac studies have
reported an increased incidence of
silent myocardial infarction.8,38 In 
patients with low IOP who show 
progressive visual fi eld (VF) and
ONH damage, systemic hypoten-
sion causing low ocular perfusion
pressure (OPP, a surrogate being the 
difference between brachial BP and
IOP) may undermine the benefi ts
of  low IOP.39-41 The risk of  GON
increases as much as six-fold in the
presence of  low OPP; a diastolic
OPP of  less than 55mmHg has
been associated with a doubling 
of  relative risk.42,43 A physiologic
nocturnal BP dip secondary to
reduced sympathetic nervous
system activity that coincides with
a nocturnal IOP spike can cause 
a pronounced OPP trough.44,45
Patients with nocturnal BP dips of
greater than 10 to 15% demonstrate 
more signifi cant retinal nerve fi ber 
layer (RNFL) and VF loss.46,47 Some
patients may experience iatrogenic
systemic hypotension secondary to
aggressive treatment of  systemic
hypertension.48,49 Indeed, aggressive
lowering of  BP has been shown to 
increase ONH cupping in patients 
without glaucoma. Signifi cant varia-
tions in OPP, like IOP, may be an
independent risk factor for GON
and VF deterioration within ten 
degrees of  fi xation.50-52 OPP may 
be increased by lowering IOP and
avoiding overtreatment of  systemic 
hypertension (of  course, deliberately 
elevating BP increases comorbidi-
ties), and its variability reduced
by smoothing IOP spikes and 
BP troughs.53
Patients with NTG often have
histories of  tinnitus, migraine 
headache, and Raynaud’s phenom-
enon, all manifestations of  primary 
vasospastic vascular dysregulation,
an imbalance between autoregula-
tory vasoconstrictor and vasodilator
stimuli.4,14 Patients with migraine,
especially women, seem particularly 
predisposed to rapid (2.6×) progres-
sion of  NTG, and lowering IOP
in women with migraine may be
less protective than in those with-
out.8,12,54 Vasospastic disease is more 
common in women, particularly 
post-menopause, and in patients of
Japanese descent, two populations
known to be at higher risk of  NTG.
Hemorrhaging within the fi ngernail
capillary bed, an accepted sign of  
vascular dysregulation, is statistically 
more common in patients with
glaucoma, particularly in those with 
a history of  disc hemorrhage, and 
may be a helpful ancillary indica-
tion of  vascular insuffi ciency.55
Reduced arterial and peripapillary 
retinal capillary blood fl ow has 
been demonstrated in patients
with NTG; many of  these patients 
exhibit vasospastic tendencies and 
asymmetric VF loss that correlates 
to interocular asymmetries in blood 
fl ow and velocity.56,57 Episodic vaso-
spasm and rebound hyperperfusion 
can lead to local infl ammation and
oxidative damage.35 Some patients 
with presumed GON and statisti-
cally normal IOP will have a history 
of  hemodynamic crisis (sudden and
severe systemic hypotension); such 
patients tend to show minimal if
any progression over time.36,37 In
fact, in an early study, Drance noted 
that nearly 90% of  patients with 
NTG had experienced transient or
sustained systemic hypoperfusion.39
While eye care practitioners rou-
tinely measure the trans-corneal 
pressure differential (the difference 
between IOP and atmospheric
pressure), what truly infl uences 
the ONH through disruption of
RGC axoplasmic fl ow is the trans-
lamina cribrosa pressure differential 
(the difference between IOP and 
orbital cerebrospinal fl uid pressure 
[CSFP]).58,59 The elevated trans-
lamina cribrosa pressure differential 
of  POAG caused by high IOP 
may be mimicked in NTG by a low 
CSFP within the optic nerve sub-
arachnoid space (ON SAS).60 CSFP
C A N A D I A N  J O U R N A L  O F  O P T O M E T R Y  |  R E V U E  C A N A D I E N N E  D ’ O P T O M É T R I EVOL 74  |  NO 4 201236
is lower in patients with NTG than 
in patients with POAG; both groups
exhibit lower CSFP than controls 
(the average being between 5 and
15mmHg), who, in turn, exhibit lower 
CSFP than patients with OHT.61,62
The inter-group CSFP differences
appear similar to the inter-group IOP
differences observed in other studies.63
Low CSFP and high trans-lamina
cribrosa pressure differential are
both positively correlated with GON 
and glaucomatous VF loss.64 The
thinning of  the lamina known to 
occur in GON may exacerbate the
trans-laminar pressure differential.
Given that pulsatile mechanical stress
is more damaging than steady, the
role of  CSFP fl uctuation, akin to 
IOP fl uctuation, is also receiving 
attention.65 In patients with NTG,
the density of  CSF in the ON SAS
is signifi cantly lower than intracranial
CSF; this impairs fl uid exchange and 
leads to relative CSF stagnation within
the ON SAS, with potentially detri-
mental impact upon RGC axons.66 All 
three pressures (IOP, OPP, and CSFP)
are independent yet interrelated, and
may be simultaneously infl uenced
by an as yet undetermined systemic
mechanism.67 Indeed, one cannot 
discount the possibility that GON 
and VF loss attributed to low OPP is
actually secondary to low CSFP, as the
latter is often found in the presence
of  systemic hypotension. Neuroimag-
ing has demonstrated a narrower ON 
SAS width in patients with NTG,
suggesting lower CSFP in that space.68
Given that direct CSFP measurement 
through lumbar puncture (LP) is
invasive and not without risk, such a
surrogate noninvasive means of  as-
sessment would certainly be of  value.
Structural Change
Some investigators feel that NTG 
exhibits an extreme amount of
ONH cupping, typifi ed by a pale, 
gently sloping, moth-eaten appear-
ance, with broad thinning of  the
inferior temporal aspect of  the
neuroretinal rim (NRR).69 Others
suggest that the disc changes in
NTG represent localized areas of
nonperfusion (a focal ischemic
glaucoma), preceding or coinciding 
with adjacent wedge or slit RNFL 
loss that results in initial severe VF
loss that is very close to fi xation.70
This type of  damage appears more 
common in female patients with a
history of  systemic vasospasm and
migraine.71 Subsequent confocal 
scanning laser ophthalmoscopic
(SLO) studies, however, found no 
signifi cant differences in optic disc
topography in cases of  POAG and
NTG.72 The rate of  progressive 
ONH damage may be greater in
patients with NTG than in those 
with POAG, particularly in patients
with already-advanced GON, where
lowering IOP may be of  marginal 
benefi t.73
First described by Bjerrum over a
century ago, rising to prominence
through the work of  Drance some 
sixty years later, the etiology of
disc hemorrhages (DH) remains
unclear. Rather than arguing cause 
versus effect (primary infarction 
versus secondary degeneration), a 
mixed-mechanism theory is gaining 
traction.74-77 These small pre-laminar 
radial fl ame- or splinter-shaped
hemorrhages occur most commonly 
at the inferior temporal aspect of
the ONH, adjacent to areas of  focal 
NRR thinning and RNFL loss, and 
within two clock hours of  areas of
beta-zone peripapillary atrophy.78-82
They are two- to fi ve-fold more 
common in patients with NTG than
in those with POAG or OHT, or
without glaucoma. Indeed, 15 to
42% of  patients with NTG demon-
strate DH at baseline or follow-up,
versus 7 to 37% of  patients with
POAG, 8% of  those with OHT,
and only 0.2 to 0.5% of  the 
non-glaucomatous population.83-88
DH are found frequently in older
patients with systemic hypertension, 
in patients with vasospastic disease, 
and in women with a history 
of  migraine.89,90 They are more 
common in the presence of  IOP
instability, and relatively rare in
patients with secondary OAG, who
typically present with signifi cant 
IOP elevation. In the Early Manifest 
Glaucoma Trial (EMGT), over
half  the participants demonstrated 
DH at least once over an average
of  eight years; most will be found
within the fi rst three to fi ve years of  
diagnosis.91 However, given that the
prevalence of  glaucoma is 2 to 4%,
up to 70% of  isolated DH will be
found in patients not (yet) diag-
nosed with the disease.83 DH are 
best detected through photography:
being transient and subtle, they are 
overlooked during clinical exam as 
often as 84% of  the time. Concur-
rent disease processes, including 
posterior vitreous detachment,
diabetes, or venous occlusion, must 
be considered in the differential
diagnosis.
DH have long been considered a
strong and independent risk factor 
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for progressive GON, increasing 
the hazard rate by a factor of  four
to six, more so in patients with
NTG than POAG, particularly in
elderly patients with pre-existing VF 
loss.92-98 In patients with OHT, DH
were strong indicators of  future
conversion to POAG, and were up
to fi ve times more common follow-
ing conversion.94 In the CNTGS,
DH was considered a reason to 
initiate or augment therapy, and was
a strong predictor of  more rapid
progression (2.7×) of  untreated 
NTG.99 Up to two-thirds of  VF
and three-quarters of  ONH show 
progressive change following DH;
VF loss may occur at two to eight 
times the rate, particularly when
DH are inferior temporal and/or 
multiple.74,77,81,90,94,98 Eyes with DH
were up to fourteen times more
likely to have a worsening of  RNFL 
status within one year. RNFL, NRR,
and VF loss can also precede DH
by weeks or months; retrospective
evaluation has indicated that all eyes
developing DH show evidence of
preexisting NRR notching.100 Eyes
with enlarging RNFL defects are
four times more likely to demon-
strate DH, with 80% occurring at 
the border between unhealthy and
healthy RNFL, suggesting that this
is the most active anatomical site
of  glaucoma progression. Such 
RNFL defects enlarge toward the
fovea nearly 90% of  the time,
causing more central VF change. In
light of  these relationships, some
investigators now consider DH a
sign of, rather than a risk factor for,
progression.101 DH become less
common in end-stage glaucoma,
and then are found nasally, adjacent 
to the only remaining viable NRR 
and peripapillary vasculature.90,95
Once DH is detected, careful docu-
mentation and vigilant follow-up is 
critical; many investigators suggest 
every few months, given that the
average duration of  DH is eight to 
ten weeks. Recurrent bleeds, often
within two years and two clock 
hours of  the initial DH, are found
in up to 73% of  patients with NTG; 
eyes that re-bleed tend to have a
signifi cantly lower IOP than eyes
with isolated DH.76,77,87 A number
of  studies suggest that patients with
recurrent DH have a higher prob-
ability of  progressive GON, RNFL 
loss, and more rapid rates of  VF
deterioration.102,103 As a rule, patients
with DH do not respond as well to 
treatment as those without.12 In fact, 
moderate IOP lowering may not al-
ter the rate of  DH, indicating a less
IOP-dependent form of  glaucoma 
requiring more aggressive pressure 
reduction even in the presence of
what would otherwise be considered
well-controlled IOP.104
Beta-zone peripapillary atrophy 
(βPPA) is an absence of  RPE and 
thinning of  Bruch’s membrane and
the choriocapillaris immediately 
adjacent to the ONH; alpha-zone 
PPA is pigment irregularity just 
peripheral to the beta-zone when
the latter is present. From a seman-
tic perspective, some argue that the 
term parapapillary is more correct 
that peripapillary, as the atrophy may 
not completely encircle the ONH. 
While present in 15 to 20% of  nor-
mal eyes, βPPA has been noted to
be larger and more frequent in eyes
with glaucoma, and is considered
an independent, location-specifi c,
and severity-dependent risk factor 
for the progression of  GON.105-108
Many believe βPPA to be more 
common in NTG, particularly in
younger patients with moderate to
severe disease.109-111 Other investiga-
tors feel that βPPA in NTG does
not differ from that in POAG, but 
still helps differentiate NTG from 
non-glaucomatous optic neu-
ropathy.112 Nasal βPPA is present 
in only 1 to 9% of  normal eyes,
but 15 to 71% of  glaucomatous
eyes; this may also aid in differential 
diagnosis.113-115 Assessing βPPA
stability may be particularly valuable 
in the evaluation of  small ONH in
which intrapapillary glaucomatous
damage can be more diffi cult to
detect.116 Conversely, βPPA may 
be less helpful in the evaluation of
oblique or highly myopic ONH and 
in patients of  Asian ethnicity, where 
peripapillary alterations are more
prevalent to begin with; ironically, 
patients with NTG are commonly 
Asian and/or myopic.117 βPPA is 
often found adjacent to an area of  
focal NRR loss and/or DH, and
large areas of  βPPA are predictive
of  future DH. Interestingly, βPPA 
and DH are associated even in the
absence of  glaucoma, suggesting 
a shared etiology of  local vascular
insuffi ciency and breakdown of
the blood-retina barrier.115 Some 
hypothesize that a disturbance of
ONH perfusion secondary to βPPA 
may result in sectoral ischemia, 
or that leakage of  vasoactive 
substances through compromised 
peripapillary vessels can damage the 
RNFL in the face of  normal IOP.109
In these cases, βPPA is felt to be a
C A N A D I A N  J O U R N A L  O F  O P T O M E T R Y  |  R E V U E  C A N A D I E N N E  D ’ O P T O M É T R I EVOL 74  |  NO 4 201238
risk factor for, rather than a sequelae 
of, glaucoma. That being said, βPPA 
is not necessarily static; progression
can be seen over time, three to fi ve
times more commonly in patients
with glaucoma, associated with 
increasing GON and VF loss.110
The presence and enlargement of
βPPA shows signifi cant correlation
with RNFL thickness and rate of
thinning (particularly in the inferior
quadrant), cup/disc ratio, mean VF
loss, and NRR area.114 βPPA shows 
a strong correlation with VF defects
within fi ve degrees of  fi xation
known to be more common in
NTG. Both the absolute scotoma
of βPPA and the relative scotoma
of  alpha-zone PPA will cause an 
enlarged blind spot. βPPA can be 
detected and monitored qualita-
tively through ophthalmoscopy and
photography, quantitatively through
imaging techniques including SLO
and optical coherence tomography 
(OCT).
Functional Change
As already noted, as many as two-
thirds of  cases of  NTG present 
with initial VF defects that threaten
fi xation; these are strong predictors
of  future VF deterioration and
visual acuity loss.118 VF defects that 
threaten fi xation are best monitored
with both 24- or 30-degree and
10-degree testing strategies. Signifi -
cant VF deterioration appears to 
occur in one-sixth to one-third of  
patients with treated NTG.93 That 
being said, recall that the CNTGS
showed that over half  the patients
with untreated NTG manifest no
discernible deterioration over fi ve to
seven years. While conventional
wisdom holds that most cases
progress slowly, there is signifi cant 
variability in rates of  progression,
even more so than in POAG: a 
ten-fold range from 0.2 to 2.0dB per
year.99 More VF loss is seen in NTG 
with higher IOP, but IOP variability 
over both short- and long-term
appears to be an important predic-
tor of, and perhaps independent 
risk factor for, glaucomatous VF 
progression, particularly in cases of
low IOP.119 The challenge, in both
NTG and POAG, is to identify 
those at risk of  rapid progression, 
and initiate early and aggressive 
treatment. Particular attention must 
be paid to localized VF progression,
which has been proven to be a
strong predictor of  future DH, and
focal GON.74 It has long been re-
ported that thinning of  the RNFL,
documented through both qualita-
tive and quantitative means, is an 
early sign of  GON, often preceding 
VF loss.120-122 Spectral domain OCT 
(SD OCT) has indicated that RNFL 
thinning is most signifi cant at the
superior and inferior temporal 
aspects of  the ONH, and correlates
strongly with VF deterioration.123
It has been proposed that loss of
17 to 20% of  age-matched average
RNFL thickness, to a level of  70
to 75 microns, is the ‘tipping point’
for structural change, whereas as 
many as half  the RGC may need
to be lost to manifest functional
(VF) change.124,125 Given that RNFL 
thickness assessed through OCT
demonstrates a fl oor effect at 
approximately 50 microns, it may 
be best to monitor early GON
through structural analysis, but 
advanced GON through functional
measures.126 Ideally, a combined
index of  structure and function 
would allow better detection, predic-
tion, and follow-up at any stage of
the disease continuum than either
parameter in isolation.127
Management
Given that IOP remains important 
in the pathogenesis of  NTG,
the use of  topical anti-glaucoma
drugs remains the mainstay of
treatment.128 The CNTGS dem-
onstrated that lowering IOP by 
30% from baseline, to an average 
of  11mmHg, reduced the risk of
progression nearly three-fold.19
That being said, 65% of  untreated
eyes showed no progression over
fi ve years of  follow-up, while up 
to 20% of  treated eyes did.8 The 
EMGT, a study in which over 50% 
of  the cohort had NTG, indicated 
that reducing IOP halved the risk 
of  glaucomatous damage, most 
signifi cantly in the face of  already-
low pressures.129,130 The conclusion 
that each 1mmHg IOP reduction 
reduced the risk of  glaucoma
damage by 10% emphasized the 
importance of  vigilant monitoring,
and that ‘last millimeter of  mercury 
of  effect’.107 This aggressiveness 
must be tempered, however, by the 
realization that glaucoma treatment 
is likely to continue for the duration
of  the patient’s life; the side effects
of  medicine and surgery on quality 
of  life must be carefully consid-
ered.131-134 Lowering peak and mean 
IOP and blunting IOP fl uctuation
decreases the risk and rate of  glau-
comatous VF loss.135 While dealing 
with an admittedly different popula-
tion, the Advanced Glaucoma
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Intervention Study (AGIS) indicated
that patients with IOP consistently 
below 18mmHg demonstrated
little if  any VF progression over six
years; even occasional elevations 
above 18mmHg resulted in more 
VF loss.135 Strict adherence to an 
individualized and appropriate target 
IOP appears to result in better VF
preservation.132 Particularly with
NTG, clinicians must realize that 
in-offi ce IOP assessment is but a
moment in time, and that structural
and functional damage may occur
exponentially with undetected IOP
spikes. This makes the goals of
lowering mean and peak IOP, and
smoothing short- and long-term
fl uctuations, equally critical. In the
presence of  extreme GON, the 
disease may become essentially 
pressure-independent, emphasizing 
the importance of  early and effec-
tive intervention.
A review of  clinical trials indicates 
that latanoprost, bimatoprost, 
timolol, and brimonidine are
effective in reducing IOP in patients 
with NTG: latanoprost seems most 
effective in reducing trough IOP 
and smoothing the diurnal curve,
while brimonidine is most effective
in reducing peak IOP, but least 
effective at trough.136 The World
Glaucoma Association recognizes 
topical carbonic anhydrase inhibi-
tors (CAI) as having a benefi cial
effect on ONH perfusion through
increasing blood fl ow velocity in
the short posterior ciliary arteries
(SPCA); prostaglandin analogs (PA)
appear to be hemodynamically 
neutral.137 PA and CAI lower both
diurnal and nocturnal IOP, whereas
beta-blockers are ineffective dur-
ing the nocturnal period. Among 
the beta-blockers, betaxolol may 
lower vascular resistance more
than timolol, leading to better 
VF preservation despite higher
treated IOP. That being said, should
treatment of  NTG be initiated, an
aggressively low target IOP (ap-
proaching episcleral venous pressure
of  approximately 10mmHg) may be 
preferable; this target may require
multiple medications or the con-
sideration of  surgery.19 In addition 
to traditional topical management, 
it has been suggested that systemic 
calcium channel blockers may be
protective in cases of  NTG through
reduction of  vasospasm; others
argue against their use due to the
potential for nocturnal systemic hy-
potension and reduced OPP.15,44,73,104
Systemic CAI may concurrently 
lower both IOP and CSFP, leaving 
the trans-lamina cribrosa pressure
differential unchanged, providing 
little benefi t in the management of
chronic glaucoma.61
As an adjunct, moderate aerobic 
exercise may be benefi cial in both
stabilizing the cardiovascular system
and reducing IOP.138
Neuroprotection is defi ned as a
therapeutic paradigm for slowing or 
preventing death of  neurons (in the 
case of  glaucoma, RGC and their
axons) in order to maintain their
physiologic function.139 Whether
secondary to excitotoxic neurotrans-
mitters (glutamate), ischemic/
oxidative injury and subsequent 
reperfusion infl ammation, blockage
of  growth factors/neurotrophins,
mitochondrial dysfunction, or
some other mechanism, apoptosis 
(programmed cell death) may 
continue independent of  the level
of  IOP.140 Glaucomatous damage is
not limited to the ONH; alterations 
in the visual pathway behind the 
globe (including lateral geniculate
nucleus and visual cortex) have
been noted in the absence of  
detectable RGC loss.141 Given that 
current treatments are limited to 
IOP-lowering, yet some patients
with glaucoma continue to progress
despite low pressures, a treatment 
that is independent of  IOP is
certainly enticing. Some current 
glaucoma medications appear to
have neuroprotective activity: in the 
Low-Pressure Glaucoma Treat-
ment Study (LoGTS), brimonidine 
demonstrated a benefi cial effect on
VF preservation independent of  
IOP-lowering; as previously noted,
dorzolamide has been proven to 
increase OPP.49,137 Memantine and 
bis(7)-tacrine (glutamate modifi ers
used in the treatment of  Alzheim-
er’s disease, a disease that may share
some basic mechanisms of  cell
death with glaucoma) are among a
growing number of  systemic agents 
being studied.142,143
In situations where there are atypical 
clinical fi ndings (age less than 50,
visual acuity less than 20/40, ONH
pallor, vertically aligned/neuro-
logic VF defects, lack of  correlation
between structural and functional
change, and/or progression at very 
low IOP) neuroimaging of  patients 
with NTG to rule out compressive 
lesions of  the optic nerve has been
suggested.16
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Conclusion
Normal-tension glaucoma is an
increasingly common, and certainly 
challenging, clinical presentation.
The challenge begins with differen-
tial diagnosis, and continues through
follow-up. Practitioners must gather,
integrate, and interpret a myriad of
data: ophthalmic and systemic, past 
and present. Given that many un-
treated patients show little progres-
sion over time, careful observation
prior to initiating therapy is certainly 
prudent. That being said, it may be
wise to consider more aggressive
treatment of  NTG in patients with
multiple risk factors – for example,
a young female with a history of
migraine presenting with a disc
hemorrhage. While the mainstay 
of  contemporary management 
remains topical IOP-lowering, the
recognition of  ocular perfusion 
and cerebrospinal fl uid pressure as
important contributing factors may 
lead to their modifi cation becoming 
part of  the treatment paradigm.
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